Jacques Henryk Camonis

Dr. Jacques Henryk Camonis


Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2014 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
MRM. Reffay
M. Reffay
MPM. C. Parrini
M. C. Parrini
OCO. Cochet-Escartin
O. Cochet-Escartin
BLB. Ladoux
B. Ladoux
ABA. Buguin
A. Buguin
PSP. Silberzan
P. Silberzan

13 June 2014 in Molecular Oncology
Verified
Journal Article
Open access
NANabil Amirouchene-Angelozzi
Nabil Amirouchene-Angelozzi
NFNémati Fariba
Némati Fariba
DGDavid Gentien
David Gentien
ANandre nicolas
andre nicolas
ADAmaury Dumont
Amaury Dumont
Sergio Roman-RomanSergio Roman-Roman
Sergio Roman-Roman
Uveal melanoma (UM) is the most common primary tumor of the eye in adults. There is no standard adjuvant treatment to prevent metastasis and no effective therapy in the metastatic setting. We have established a unique panel of 7 UM cell lines from either patient's tumors or patient‐derived tumor xenografts (PDXs). This panel recapitulates the molecular landscape of the disease in terms of genetic alterations and mutations. All the cell lines display GNAQ or GNA11 activating mutations, and importantly four of them display BAP1 (BRCA1 associated protein‐1) deficiency, a hallmark of aggressive disease. The mTOR pathway was shown to be activated in most of the cell lines independent of AKT signaling. mTOR inhibitor Everolimus reduced the viability of UM cell lines and significantly delayed tumor growth in 4 PDXs. Our data suggest that mTOR inhibition with Everolimus, possibly in combination with other agents, may be considered as a therapeutic option for the management of uveal melanoma.

1 January 2006 in Molecular and Cellular Biology
Verified
Journal Article
Closed access
PDF file
CRCarine Rossé
Carine Rossé
AHAnastassia Hatzoglou
Anastassia Hatzoglou
MPMaria-Carla Parrini
Maria-Carla Parrini
MWMichael A. White
Michael A. White
PCPhilippe Chavrier
Philippe Chavrier
JCJacques Henryk Camonis
Jacques Henryk Camonis
The Ras family GTPases RalA and RalB have been defined as central components of the regulatory machinery supporting tumor initiation and progression. Although it is known that Ral proteins mediate oncogenic Ras signaling and physically and functionally interact with vesicle trafficking machinery, their mechanistic contribution to oncogenic transformation is unknown. Here, we have directly evaluated the relative contribution of Ral proteins and Ral effector pathways to cell motility and directional migration. Through loss-of-function analysis, we find that RalA is not limiting for cell migration in normal mammalian epithelial cells. In contrast, RalB and the Sec6/8 complex or exocyst, an immediate downstream Ral effector complex, are required for vectorial cell motility. RalB expression is required for promoting both exocyst assembly and localization to the leading edge of moving cells. We propose that RalB regulation of exocyst function is required for the coordinated delivery of secretory vesicles to the sites of dynamic plasma membrane expansion that specify directional movement.

14 October 2012 in Nature Methods
Verified
Journal Article
Closed access
MDMaxime Deforet
Maxime Deforet
MPMaria Carla Parrini
Maria Carla Parrini
LPLaurence Petitjean
Laurence Petitjean
MBMarco Biondini
Marco Biondini
ABAxel Buguin
Axel Buguin
PSPascal Silberzan
Pascal Silberzan

1 February 2003 in Molecular and Cellular Biology
Verified
Journal Article
Open access
PDF file
Gladys MireyGladys Mirey
Gladys Mirey
MBMaria Balakireva
Maria Balakireva
SLSébastien L'HOste
Sébastien L'HOste
CRCarine Rossé
Carine Rossé
SVStéphanie Voegeling
Stéphanie Voegeling
JCJacques Henryk Camonis
Jacques Henryk Camonis
Ras GTPases are central to many physiological and pathological signaling pathways and act via a combination of effectors. In mammals, at least three Ral exchange factors (RalGEFs) contain a Ras association domain and constitute a discrete subgroup of Ras effectors. Despite their ability to bind activated Rap as well as activated Ras, they seem to act downstream of Ras but not downstream of Rap. We have revisited the Ras/Rap-Ral connections in Drosophila melanogaster by using iterative two-hybrid screens with these three GTPases as primary baits and a subsequent genetic approach. We show that (i) the Ral-centered protein network appears to be extremely conserved in human and flies, (ii) in this network, RGL is a functional Drosophila orthologue of RalGEFs, and (iii) the RGL-Ral pathway functionally interacts with both the Ras and Rap pathways. Our data do not support the paradigmatic model where Ral is in the effector pathway of Ras. They reveal a signaling circuitry where Ral is functionally downstream of the Rap GTPase, at odds with the pathways described for mammalian cell lines. Thus, in vivo data show variations in the connectivity of pathways described for cell lines which might display only a subset of the biological possibilities.

1 October 2015 in Current Biology
Verified
Journal Article
Open access
CJCarine Joffre
Carine Joffre
NDNicolas Dupont
Nicolas Dupont
LHLily Hoa
Lily Hoa
VGValenti Gomez
Valenti Gomez
RPRaul Pardo
Raul Pardo
JCJacques Henryk Camonis
Jacques Henryk Camonis
Autophagy plays key roles in development, oncogenesis, cardiovascular, metabolic, and neurodegenerative diseases. Hence, understanding how autophagy is regulated can reveal opportunities to modify autophagy in a disease-relevant manner. Ideally, one would want to functionally define autophagy regulators whose enzymatic activity can potentially be modulated. Here, we describe the STK38 protein kinase (also termed NDR1) as a conserved regulator of autophagy. Using STK38 as bait in yeast-two-hybrid screens, we discovered STK38 as a novel binding partner of Beclin1, a key regulator of autophagy. By combining molecular, cell biological, and genetic approaches, we show that STK38 promotes autophagosome formation in human cells and in Drosophila. Upon autophagy induction, STK38-depleted cells display impaired LC3B-II conversion; reduced ATG14L, ATG12, and WIPI-1 puncta formation; and significantly decreased Vps34 activity, as judged by PI3P formation. Furthermore, we observed that STK38 supports the interaction of the exocyst component Exo84 with Beclin1 and RalB, which is required to initiate autophagosome formation. Upon studying the activation of STK38 during autophagy induction, we found that STK38 is stimulated in a MOB1- and exocyst-dependent manner. In contrast, RalB depletion triggers hyperactivation of STK38, resulting in STK38-dependent apoptosis under prolonged autophagy conditions. Together, our data establish STK38 as a conserved regulator of autophagy in human cells and flies. We also provide evidence demonstrating that STK38 and RalB assist the coordination between autophagic and apoptotic events upon autophagy induction, hence further proposing a role for STK38 in determining cellular fate in response to autophagic conditions.